BVT Call 100 ABT 20.12.2024/ DE000VD60W76 /
2024-10-10 10:13:45 AM | Chg.0.000 | Bid10:37:00 AM | Ask10:37:00 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.600EUR | 0.00% | 1.610 Bid Size: 23,000 |
1.640 Ask Size: 23,000 |
Abbott Laboratories | 100.00 USD | 2024-12-20 | Call |
GlobeNewswire
08-06
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
GlobeNewswire
06-06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
05-09
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
03-25
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
03-15
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
2023-11-14
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
2023-10-19
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
2023-10-10
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
2023-10-02
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors